HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can Gene-Edited immune cells tame Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: CoRegen, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer pill HLX97 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC